DE551180T1 - Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. - Google Patents

Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.

Info

Publication number
DE551180T1
DE551180T1 DE93300048T DE93300048T DE551180T1 DE 551180 T1 DE551180 T1 DE 551180T1 DE 93300048 T DE93300048 T DE 93300048T DE 93300048 T DE93300048 T DE 93300048T DE 551180 T1 DE551180 T1 DE 551180T1
Authority
DE
Germany
Prior art keywords
cystinuria
treatment
bucillamine
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE93300048T
Other languages
English (en)
Inventor
Hisashi Baba
Hideo Takashina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of DE551180T1 publication Critical patent/DE551180T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (3)

PATENTANSPRÜCHE
1. Die Verwendung von Bucillamine oder eines entsprechenden pharmazeutisch annehmbaren Salzes zur Behandlung und/oder Vorbeugung von
Cystinuria.
2. Die Verwendung von Buci11 amine oder eines entsprechenden pharmazeutisch annehmbaren Salzes zur Herstellung eines Arzneimittels zur Behandlung und/oder Vorbeugung von Cystinuria.
3. Die Verwendung nach Anspruch 1 oder 2, wobei das pharmazeutisch annehmbare Salz ausgewählt wird zwischen Natriumsalz und Kaliumsalz.
DE93300048T 1992-01-10 1993-01-06 Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. Pending DE551180T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4040037A JP2814033B2 (ja) 1992-01-10 1992-01-10 シスチン尿症治療剤

Publications (1)

Publication Number Publication Date
DE551180T1 true DE551180T1 (de) 1994-02-03

Family

ID=12569714

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69300037T Expired - Fee Related DE69300037T2 (de) 1992-01-10 1993-01-06 Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE93300048T Pending DE551180T1 (de) 1992-01-10 1993-01-06 Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69300037T Expired - Fee Related DE69300037T2 (de) 1992-01-10 1993-01-06 Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.

Country Status (5)

Country Link
US (1) US5266595A (de)
EP (1) EP0551180B1 (de)
JP (1) JP2814033B2 (de)
DE (2) DE69300037T2 (de)
ES (1) ES2049711T3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670545A (en) * 1996-02-09 1997-09-23 Board Of Regents Of The University Of Colorado Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species
AU5428300A (en) 1999-06-21 2001-01-09 Santen Pharmaceutical Co. Ltd. Remedies for arthrosis deformans
US20060275279A1 (en) * 2005-06-06 2006-12-07 Rozzell J D Methods for dissolving cystine stones and reducing cystine in urine
EP2922536A4 (de) * 2012-11-20 2016-06-08 Revive Therapeutics Inc Verwendung von bucillamin zur behandlung von gicht
EP3658130A4 (de) * 2017-07-25 2021-04-21 Altibio, Inc. Bucillaminzusammensetzungen mit modifizierter freisetzung, kits und verfahren zur behandlung von cystinurie, arthritis, gicht und verwandten krankheiten
CN114269722A (zh) * 2019-07-26 2022-04-01 贝尔维奇生物医学研究所(伊迪贝尔) 麦角硫因、s-甲基-麦角硫因及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS535112A (en) * 1976-03-08 1978-01-18 Santen Pharmaceutical Co Ltd New cysteine derivatives

Also Published As

Publication number Publication date
DE69300037T2 (de) 1995-06-29
EP0551180B1 (de) 1994-12-28
ES2049711T1 (es) 1994-05-01
DE69300037D1 (de) 1995-02-09
US5266595A (en) 1993-11-30
JP2814033B2 (ja) 1998-10-22
ES2049711T3 (es) 1995-06-01
JPH05186341A (ja) 1993-07-27
EP0551180A1 (de) 1993-07-14

Similar Documents

Publication Publication Date Title
IE780643L (en) THERAPEUTIC APPLICATION OF d, 1-CARNITINE DERIVITIVES
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
CA2213339A1 (en) Method of treating adenosine depletion
IT8848251A0 (it) Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
DE551180T1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
EP0342587A3 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
DE3483944D1 (de) Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension.
NZ268039A (en) Use of efaroxan in treating parkinson's disease
RU97104062A (ru) Применение селегилина для лечения эпилептических заболеваний
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
IT1244562B (it) Agente per la prevenzione ed il trattamento dell'opacita' del cristallino.
ATE89726T1 (de) Erhoehung des ausfliessens waessriger koerperfluessigkeit.
DE3674323D1 (de) 4-methoxyisophthalsaeurederivat mit pharmakologischer wirksamkeit gegen thromboembolische erkrankung und verfahren zu dessen herstellung.
EP0202986A3 (en) Use of "naftidrofuryl" in the treatment of neuropathies
HU9502320D0 (en) Use of inhibitors of ornitine aminotransferase for the manufacture of a medicament for the treatment of alzheimer's disease and process to prepare (2s,5s)-5-fluoromethylornithine
ES8307711A1 (es) "procedimiento para la preparacion de un nuevo derivado de alquilenodiamina".
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
FI933872A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4h)-on-derivat
RU96122561A (ru) Способ комплексной терапии заболеваний
IT8922312A0 (it) Nuovo metodo di trattamento dell'aritmia ventricolare
RU97112901A (ru) Тромболитические средства
RU93004798A (ru) Новые азетидиновые производные пиридонкарбоновых кислот, способ их получения, фармацевтическая композиция на их основе и использование
RU96104214A (ru) Способ лечения транссудативных форм центральных хориоретинальных дистрофий